| Products/Services Used | Details | Operation |
|---|---|---|
| Peptide Synthesis | … WT or D3RKO DCs were loaded with OVA protein (1 mg/ml) or with OVA-derived peptides OVA 257–264 (0.1 ng/ml) or OVA 323–339 (200 ng/ml) (both from GenScript Corp., Piscataway, NJ), and then matured with LPS (400 ng/ml) in the presence or absence of PG01037 (10 … | Get A Quote |
Dendritic cells (DCs) display the unique ability for cross-presenting antigens to CD8 T-cells， promoting their differentiation into cytotoxic T-lymphocytes (CTLs)， which play a pivotal role in anti-tumor immunity. Emerging evidence points to dopamine receptor D3 (D3R) as a key regulator of immunity. Accordingly， we studied how D3R regulates DCs function in anti-tumor immunity. The results show that D3R-deficiency in DCs enhanced expansion of CTLs in vivo and induced stronger anti-tumor immunity. Co-culture experiments indicated that D3R-inhibition in DCs potentiated antigen cross-presentation and CTLs activation. Our findings suggest that D3R in DCs constitutes a new therapeutic target to strengthen anti-... More
